Humana (NYSE:HUM) Issues Earnings Results, Beats Expectations By $0.10 EPS

Humana (NYSE:HUM) posted its quarterly earnings results on Tuesday. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10, Zacks reports. Humana had a net margin of 1.18% and a return on equity of 13.20%. Humana updated its FY 2025 guidance to 16.250-16.250 EPS.

Humana Stock Performance

Shares of NYSE HUM opened at $266.91 on Tuesday. The business’s 50-day simple moving average is $274.21 and its 200-day simple moving average is $297.52. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana has a 52 week low of $213.31 and a 52 week high of $406.46. The firm has a market cap of $32.14 billion, a price-to-earnings ratio of 23.64, a P/E/G ratio of 2.11 and a beta of 0.56.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and boosted their target price for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Morgan Stanley upped their price objective on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Truist Financial lifted their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Barclays raised their price objective on shares of Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 22nd. Finally, Piper Sandler boosted their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $297.68.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.32% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.